Clinical trial
Prolonging the Response by Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia: a Randomized Placebo-controlled Trial - the PROLONG Trial
NCT03010202 is registered in ClinicalTrials.gov with Ostfold Hospital Trust as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prolonging the Response by Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia: a Randomized Placebo-controlled Trial - the PROLONG Trial
- Lead sponsor
- Ostfold Hospital Trust
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 11, 2017
- Completion date
- December 31, 2024
- Enrollment
- 136 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.